ReviewActa bio-medica : Atenei Parmensis2018
Current treatment of hypoparathyroidism: Theory versus reality waiting guidelines for children and adolescents.
Review in Acta bio-medica : Atenei Parmensis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- Refractory hypocalcaemia-induced laryngeal spasm requiring emergency intubation in a malnourished young woman: overcoming diagnostic and therapeutic barriers in resource-limited settings.International journal of emergency medicine · 2026Article
- Late-Onset Hypoparathyroidism-Induced Hypocalcemia in a Very Low Birth Weight Infant Caused by Undiagnosed Maternal Hyperparathyroidism.AJP reports · 2026Article
- First Reported Use of Recombinant Parathyroid Hormone in Kenny-Caffey Syndrome Type 2: A Case Report and Literature Review.Diseases (Basel, Switzerland) · 2026Review
- Key Clinical and X-Ray Characteristics for the Diagnosis of Kenny-Caffey Syndrome Types 1 and 2.Molecular syndromology · 2025Article
- HomozygousJournal of pediatric genetics · 2024Article
- Neonatal Severe Hyperparathyroidism Causing Life-Threatening Hypercalcemia Treated With Medical and Surgical Management.JCEM case reports · 2024Article
- Recurrent hypocalcemic tetany presenting to the emergency room: Answers.Pediatric nephrology (Berlin, Germany) · 2022Article
- Teriparatide Therapy in a 4-Month-Old With Severe Hypoparathyroidism.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2022Article
- A child with tetany, convulsions, and nephrocalcinosis: Answers.Pediatric nephrology (Berlin, Germany) · 2021Article
- A novel case of neonatal severe hyperparathyroidism successfully treated with a type II calcimimetic drug.Bone reports · 2021Article
- Case Report: Severe Hypocalcemic Episodes Due to Autoimmune Enteropathy.Frontiers in endocrinology · 2021Article
- Unique classification of parathyroid dysfunction in patients with transfusion dependent thalassemia major using Nomogram-A cross sectional study.Annals of medicine and surgery (2012) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The diagnosis of hypoparathyroidism(HPT)is readily made in the presence of hypocalcemia with markedly reduced or absent parathormone (PTH) levels. Currently available treatments for HPT include high dose vitamin D (ergocalciferol, D2 and cholecalciferol, D3) or, the active metabolite dihydroxy vitamin D (calcitriol), in addition to calcium supplements.This regimen, if not well monitored, can lead to hypercalciuria, as PTH deficiency impairs renal calcium reabsorption. Thus the goal of treatment, is to maintain serum calcium at the low end of the normal range. Undertreatment can cause symptomatic hypocalcemia, while overtreatment hypercalciuria, which may lead to nephrolithiasis, nephrocalcinosis, and renal insufficiency. At present, there is no consensus on the management of HPT in children and adolescents and only few studies are available on the long term outcome of patients with recombinant HPT treatment. The purpose of this article is to review, in a comprehensive manner, the major aspects of HPT management in children and adolescents waiting for authoritative guidelines for the treatment of HPT in this group of patients. Further research, addressing specific questions for this population are urgently needed to improve long-term safety of patients. Educational interventions are also needed for professionals, parents and patients to enable them to improve knowledge, quality of life and effective management care at home.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.